COPENHAGEN, FEBRUARY 7, 2019 - UNION therapeutics A/S (UNION) today announced that it has entered into a strategic veterinary partnership with Ceva Santé Animale S.A. (Ceva) on the candidate UNI836.
Under the agreement, Ceva will be developing UNI836 for treatment of canine pyoderma. Canine pyoderma is one of the most frequent diseases in companion animals and a significant burden for both animal patients and their owners.
Chief Executive Officer of UNION, Dr. Rasmus Toft-Kehler, commented: “We appreciate to be collaborating with one of the fastest growing veterinary care companies on broadening the utility of the compound class. The results generated in collaboration with Ceva indicates that UNI836 has the potential to become a new and highly innovative treatment for companion animals and their owners”. Dr. Morten Sommer, Chief Scientific Officer of UNION, further commented: “Our collaborative efforts have highlighted the novel mechanism of action underlying UNI836 to provide an interesting approach to tackle an unmet medical need in the veterinary space. We look forward to continue working with Ceva on the advancement of UNI836 for treatment of canine pyoderma”.
Dr. Pascal Anjot, VP Global R&D & Innovation, Ceva added: "We are very pleased to be associated with UNION therapeutics for the development of this new opportunity in the treatment of Pyoderma in companion animals. Ceva has long been at the forefront of promoting the rational use of antibiotics in veterinary medicine. The GRAM (Guidance for the Rational use of Antimicrobials) initiative developed together with leading European experts is a good example and this new project with UNION offers to provide veterinarians with a very innovative, therapeutic approach to the treatment of this condition, in line with this aim of continually developing best practice".
As part of the agreement, Ceva will be taking responsibility for further development and global commercialization of UNI836.
UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. The leadership team of UNION has invented and successfully developed more than 10 approved human medicines. In 2018, these medicines saved thousands of lives and generated revenues of more than 5 Billion USD. UNION is headquartered in Copenhagen (Denmark) and managed by a global team across Europe and USA.
Ceva Santé Animale is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Ceva’s mission summarised in the slogan, "Together, beyond animal health", recognises that the future health of animals, humans and our planet are inseparably bound together. Ceva is directly present in 45 countries around the world and have active business in over 110.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.